Regulus Therapeutics Inc. (RGLS)
Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)
8.16
+0.02 (0.25%)
Inactive · Last trade price on Jun 24, 2025
Regulus Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 10.01M | 3.17M | 46.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRGLS News
- 4 months ago - Novartis completes acquisition of Regulus Therapeutics - GlobeNewsWire
- 4 months ago - Novartis announces expiration of Regulus Therapeutics tender offer - GlobeNewsWire
- 5 months ago - Novartis announces commencement of tender offer to acquire Regulus Therapeutics - GlobeNewsWire
- 6 months ago - Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - PRNewsWire
- 6 months ago - REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS - Business Wire
- 6 months ago - Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga
- 6 months ago - Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga
- 6 months ago - Novartis to Acquire Regulus in $1.7 Billion Deal - WSJ